UG HEALTHCARE CORPORATION LTD (SGX:41A)
UG Healthcare - Higher ASPs On The Cards
- We reiterate our positive view on UG Healthcare (SGX:41A) as we believe higher ASPs are on the cards given the surge in glove demand.
- We now impute 20% ASP q-o-q growth for UG Healthcare’s OBM gloves in 4QFY6/20F and 1QFY21F into our model. Our FY20-22F EPS is lifted by 9.2%-57.2%.
- Despite the recent rally, we believe UG Healthcare’s valuation remains attractive at 11.2x CY21F P/E.
- Reiterate ADD with a higher Target Price of S$2.10.
Quantum of ASP hike likely to be higher than expected
- Our recent channel checks suggest that Malaysian-based glove makers have hiked their average selling prices (ASPs) at a faster rate than our forecasts. For example, we gather that Supermax’s ASPs likely saw a c.35% q-o-q increase in the Apr-Jun 2020 quarter. We believe this reflects the urgent demand for gloves, as daily new cases of Covid-19 worldwide continue to be on an uptrend.
- We now impute a 20% ASP growth q-o-q for UG Healthcare’s own brand manufacturing (OBM) gloves (which accounts for c.70% sales volume) in 4QFY6/20F and 1QFY21F into our model. We forecast UG Healthcare’s current ASPs to hold up till 1Q21, before a gradual normalisation of prices as higher industry supply kicks in.
- Our FY20-22F EPS for UG Healthcare is lifted by 9.2%-57.2% mainly to account for higher ASPs.
Forecasting record-breaking 2HFY20F results
- UG Healthcare is set to announce its 2HFY6/20F results by mid-Aug 2020. We expect UG Healthcare to record a sequentially stronger net profit of S$10.1m in 2HFY20F, a 11.9x jump on a hoh basis. This will be mainly driven by:
- higher ASPs,
- lower raw material prices, and
- cost savings from internal efficiency enhancements and better economies of scale.
- Our forecasted EBITDA margins for 2HFY20F/FY21F stand at 19.0%/27.2%, at the lower-end of glove makers under our coverage.
Reiterate ADD, with a higher Target Price of S$2.10
- UG Healthcare remains our preferred pick among the Singapore-listed rubber glove sector, due to its undemanding valuation (a c.60% discount to the Malaysia-listed glove sector average CY21F P/E of 29.3x) and OBM business model, which allows it to garner stronger ASP upside potential vs. its peers given the current strong surge in glove demand.
- Our Target Price for UG Healthcare is lifted to S$2.10, still pegged to 15.0x CY21F P/E to reflect the current favourable operating environment for glove players.
- See UG Healthcare Share Price; UG Healthcare Target Price; UG Healthcare Analyst Reports; UG Healthcare Dividend History; UG Healthcare Announcements; UG Healthcare Latest News.
- Potential re-rating catalysts include further price hikes.
- Downside risks include earlier ASP normalisation.
- (UG Healthcare is one of the best performers among the top 100 most active stocks in 1H20 as highlighted in SGX market update: Singapore’s Most Defensive Stocks in 1H20)
- See report on another SGX listed glove maker - Riverstone Holdings - CGS-CIMB Research 2020-07-08: Stronger Price Increases In 3Q20F, and also report Rubber Gloves - CGS-CIMB Research 2020-07-01: No Concern On Lower ASPs & Oversupply.
ONG Khang Chuen CFA
CGS-CIMB Research
|
https://www.cgs-cimb.com
2020-07-08
SGX Stock
Analyst Report
2.10
UP
1.360
